Cipher Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Cipher Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 13.5% bzw. 8.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 12.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11% betragen.

Wichtige Informationen

13.5%

Wachstumsrate der Gewinne

11.98%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	42.9%
Wachstumsrate der Einnahmen	8.7%
Zukünftige Eigenkapitalrendite	10.95%
Analystenabdeckung	Low
Zuletzt aktualisiert	09 May 2025

Jüngste Aktualisierungen zum künftigen Wachstum

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

Recent updates

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

May 09

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Apr 28

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

Feb 23 Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Dec 13

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Nov 14

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Nov 12

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 09

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26

Gewinn- und Umsatzwachstumsprognosen

TSX:CPH - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2027	62	19	N/A	24	2
12/31/2026	58	17	N/A	25	3
12/31/2025	51	14	N/A	23	3
3/31/2025	40	9	-59	21	N/A
12/31/2024	33	12	-60	20	N/A
9/30/2024	26	16	-67	13	N/A
6/30/2024	22	23	17	17	N/A
3/31/2024	22	23	14	14	N/A
12/31/2023	21	20	16	16	N/A
9/30/2023	21	32	15	15	N/A
6/30/2023	20	28	13	13	N/A
3/31/2023	20	27	13	13	N/A
12/31/2022	21	27	11	11	N/A
9/30/2022	22	10	15	15	N/A
6/30/2022	21	8	11	11	N/A
3/31/2022	22	9	11	11	N/A
12/31/2021	22	8	14	14	N/A
9/30/2021	22	5	14	14	N/A
6/30/2021	23	6	12	12	N/A
3/31/2021	21	3	11	11	N/A
12/31/2020	22	4	11	12	N/A
9/30/2020	21	7	7	7	N/A
6/30/2020	22	3	10	11	N/A
3/31/2020	23	4	11	12	N/A
12/31/2019	22	3	7	8	N/A
9/30/2019	23	-1	6	8	N/A
6/30/2019	22	2	4	6	N/A
3/31/2019	23	3	0	2	N/A
12/31/2018	23	1	N/A	8	N/A
9/30/2018	28	6	N/A	13	N/A
6/30/2018	34	9	N/A	18	N/A
3/31/2018	37	11	N/A	19	N/A
12/31/2017	40	11	N/A	13	N/A
9/30/2017	34	7	N/A	11	N/A
6/30/2017	32	5	N/A	9	N/A
3/31/2017	31	1	N/A	10	N/A
12/31/2016	30	4	N/A	11	N/A
9/30/2016	33	6	N/A	8	N/A
6/30/2016	34	2	N/A	7	N/A
3/31/2016	34	1	N/A	7	N/A
12/31/2015	34	2	N/A	8	N/A
9/30/2015	32	3	N/A	12	N/A
6/30/2015	30	13	N/A	16	N/A
3/31/2015	30	18	N/A	19	N/A
12/31/2014	29	19	N/A	25	N/A
9/30/2014	33	31	N/A	23	N/A
6/30/2014	32	27	N/A	18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CPHDas prognostizierte Gewinnwachstum (13.5% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: CPHDie Erträge des Unternehmens (13.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Canadian (13.9% pro Jahr).

Hohe Wachstumserträge: CPHDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CPHDie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Canadian (4.8% pro Jahr).

Hohe Wachstumseinnahmen: CPHDie Einnahmen des Unternehmens (8.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CPHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2025/05/12 17:58
Aktienkurs zum Tagesende	2025/05/09 00:00
Gewinne	2025/03/31
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Cipher Pharmaceuticals Inc. wird von 13 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Douglas Loe	Byron Capital Markets
Tania Armstrong-Whitworth	Canaccord Genuity
Prakash Gowd	CIBC Capital Markets

Cipher Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.0% to CA$15.65

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Price target increased by 7.4% to CA$17.37

Consensus EPS estimates increase by 10%

Consensus revenue estimates increase by 37%

Recent updates

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable

Cipher Pharmaceuticals Inc. to Report Q1, 2025 Results on May 08, 2025

Investor sentiment improves as stock rises 20%

Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2025

Price target decreased by 7.0% to CA$15.65

Lead Independent Director exercised options and sold CA$64k worth of stock

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Cipher Pharmaceuticals Inc. to Report Q4, 2024 Results on Mar 18, 2025

Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence

We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt

Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think

Investor sentiment deteriorates as stock falls 15%

With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For

Price target increased by 10% to CA$18.59

Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Third quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 7.4% to CA$17.37

Cipher Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 07, 2024

Cipher Pharmaceuticals Inc. Appoints Hamed Ghanei as Chief Business Officer

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 19%

Consensus EPS estimates increase by 10%

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. Announces CFO Changes

Cipher Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024

Consensus revenue estimates increase by 37%

Investor sentiment improves as stock rises 16%

First quarter 2024 earnings released: EPS: US$0.21 (vs US$0.10 in 1Q 2023)

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 14, 2024

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Investor sentiment improves as stock rises 27%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q4, 2023 Results on Mar 14, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 53%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cipher Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment improves as stock rises 15%

Cipher Pharmaceuticals Inc. (TSX:CPH) announces an Equity Buyback for CAD 6 million worth of its shares.

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Consensus EPS estimates increase by 17%

Consensus revenue estimates decrease by 12%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q1, 2023 Results on May 11, 2023

Interim CEO & Chairman of the Board exercised options to buy CA$411k worth of stock.

Interim CEO & Chairman of the Board exercised options to buy CA$462k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. Declares Quarterly Dividend, Payable on or About February 28, 2023

Independent Director recently sold CA$61k worth of stock

Price target increased to CA$4.13

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cipher Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 10, 2022

Second quarter 2022 earnings released: EPS: US$0.08 (vs US$0.10 in 2Q 2021)

Cipher Pharmaceuticals Inc. Announces Appointment of Bryan Jacobs as Chief Financial Officer

Cipher Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 11, 2022

John Mull Decides Not to Stand for Re-Election as Director of Cipher Pharmaceuticals Inc

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

First quarter 2022 earnings: EPS exceeds analyst expectations

Cipher Pharmaceuticals Inc. to Report Q1, 2022 Results on May 12, 2022

Price target increased to CA$3.30

Cipher Pharmaceuticals Inc., Annual General Meeting, Jun 22, 2022

Full year 2021 earnings: EPS exceeds analyst expectations